Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Safety and Tolerability Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT02705469 is registered in ClinicalTrials.gov with Zenith Epigenetics as lead sponsor.

NCT NCT02705469
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02705469 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Safety and Tolerability Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
Zenith Epigenetics
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2016
Completion date
October 31, 2017
Enrollment
44 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer